Sophia Genetics SA
SOPH3.270USD
+0.110+3.48%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
218.51MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Sophia Genetics SA Unternehmen
Sophia Genetics SA is a Switzerland-based company engaged in the software publishing sector. The Company offer a cloud-based Software-as-a-Service platform - the SOPHiA DDM, which is data-driven medicine platform enabling insights from disparate, complex datasets to improve diagnosis, treatment, and drug development. The Company has offices in Switzerland, France and the United Kingdom and operates worldwide.
Unternehmensinformationen
BörsenkürzelSOPH
Name des UnternehmensSophia Genetics SA
IPO-datumJul 23, 2021
CEODr. Jurgi Camblong, Ph.D.
Anzahl der mitarbeiter423
WertpapierartOrdinary Share
GeschäftsjahresendeJul 23
AddresseLa Piece 12
StadtROLLE
BörseNASDAQ Global Select Consolidated
LandSwitzerland
Postleitzahl1180
Telefon41216941060
Websitehttps://www.sophiagenetics.com/
BörsenkürzelSOPH
IPO-datumJul 23, 2021
CEODr. Jurgi Camblong, Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Jurgi Camblong, Ph.D.
Dr. Jurgi Camblong, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
2.65M
+7.89%
Dr. Vincent Ossipow, Ph.D.
Dr. Vincent Ossipow, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
443.81K
+12.21%
Dr. Zhenyu Xu, Ph.D.
Dr. Zhenyu Xu, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
396.61K
-4.26%
Mr. Troy M. Cox
Mr. Troy M. Cox
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
234.25K
+25.98%
Mr. Didier Hirsch
Mr. Didier Hirsch
Non-Executive Independent Director
Non-Executive Independent Director
133.93K
+79.72%
Mr. Ross J Muken
Mr. Ross J Muken
President
President
128.13K
+108.22%
Ms. Manuela Da Silva Valente
Ms. Manuela Da Silva Valente
Chief People Officer
Chief People Officer
60.38K
+51.32%
Dr. Philippe Menu, M.D., Ph.D.
Dr. Philippe Menu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
39.60K
-5.14%
Mr. Milton G. Silva-Craig, J.D.
Mr. Milton G. Silva-Craig, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. George A. Cardoza
Mr. George A. Cardoza
Chief Financial Officer
Chief Financial Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Jurgi Camblong, Ph.D.
Dr. Jurgi Camblong, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
2.65M
+7.89%
Dr. Vincent Ossipow, Ph.D.
Dr. Vincent Ossipow, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
443.81K
+12.21%
Dr. Zhenyu Xu, Ph.D.
Dr. Zhenyu Xu, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
396.61K
-4.26%
Mr. Troy M. Cox
Mr. Troy M. Cox
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
234.25K
+25.98%
Mr. Didier Hirsch
Mr. Didier Hirsch
Non-Executive Independent Director
Non-Executive Independent Director
133.93K
+79.72%
Mr. Ross J Muken
Mr. Ross J Muken
President
President
128.13K
+108.22%
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
Rest of EMEA
5.51M
31.00%
France
2.61M
14.70%
Italy
2.53M
14.23%
United States
2.48M
13.95%
Spain
1.42M
7.97%
Other
3.23M
18.15%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Wed, Jul 23
Aktualisiert: Wed, Jul 23
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Alychlo NV
10.46%
Generation Investment Management LLP
10.16%
aMoon Fund
8.25%
UBS Asset Management (Switzerland)
6.79%
Akre Capital Management, LLC
5.57%
Other
58.78%
Aktionäre
Aktionäre
Anteil
Alychlo NV
10.46%
Generation Investment Management LLP
10.16%
aMoon Fund
8.25%
UBS Asset Management (Switzerland)
6.79%
Akre Capital Management, LLC
5.57%
Other
58.78%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
17.54%
Investment Advisor/Hedge Fund
16.07%
Venture Capital
13.28%
Family Office
10.52%
Individual Investor
6.53%
Hedge Fund
0.91%
Bank and Trust
0.46%
Pension Fund
0.14%
Other
34.55%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
89
36.68M
54.88%
-257.44K
2025Q1
93
36.63M
54.82%
-389.48K
2024Q4
93
32.50M
49.36%
-965.83K
2024Q3
91
34.60M
52.08%
+657.87K
2024Q2
92
32.44M
48.93%
+1.33M
2024Q1
93
31.91M
48.51%
+375.11K
2023Q4
91
30.61M
46.76%
-676.23K
2023Q3
91
30.34M
46.61%
-4.34M
2023Q2
90
31.34M
48.19%
-3.70M
2023Q1
86
30.07M
46.79%
+1.58M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Alychlo NV
6.99M
10.46%
--
--
Feb 15, 2025
Generation Investment Management LLP
6.79M
10.16%
--
--
Mar 31, 2025
aMoon Fund
5.51M
8.25%
+577.36K
+11.70%
Feb 15, 2025
UBS Asset Management (Switzerland)
4.54M
6.79%
+2.34M
+106.14%
Mar 31, 2025
Akre Capital Management, LLC
3.72M
5.57%
+1.48M
+66.22%
Jun 20, 2025
Balderton Capital (UK) LLP
3.36M
5.03%
--
--
Feb 15, 2025
UBS Asset Management (Americas) LLC
3.10M
4.64%
+3.10M
--
Mar 31, 2025
Camblong (Jurgi)
2.65M
3.97%
+194.16K
+7.89%
Feb 15, 2025
Banque Pictet & Cie S.A.
2.21M
3.31%
-32.20K
-1.44%
Mar 31, 2025
Principal Global Investors (Equity)
1.39M
2.07%
-43.33K
-3.03%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Health Innovation Active ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
iShares Health Innovation Active ETF
Anteil0%
Fidelity Nasdaq Composite Index ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
